Robin Ali is Professor of Human Molecular Genetics at UCL Institute of Ophthalmology, London where he is also Head of Department of Genetics. He also holds faculty positions at UCL Institute of Child Health and the Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital.
The main focus of his research is the development of gene and cell therapy for the treatment of retinal disorders. Robin Ali and members of his team have received numerous prizes and awards for their work on developing new treatments for retinal degeneration including the Pfizer /ARVO Karl Camras Translational Award in 2010 and Alcon Research Institute Award in 2009. In 2007 he was elected to the UK Academy of Medical Sciences and in 2009 appointed Senior Investigator of The UK National Institute of Health Research.
He serves on the advisory boards of a number of funding bodies including the UK Medical Research Council (Neurosciences and Mental Health Board and the Translational Stem Cell Research Committee) as well as the advisory boards of pharmaceutical and biotech companies, including Alcon Pharmaceuticals and ReGenX.
He is also Associate Director of Research at Fighting Blindness. He obtained his BSc (1988) and PhD in Genetics (1993) at University College London, continued by postdoctoral training at the MRC National Institute for Medical Research and UCL Institute of Ophthalmology and established his laboratory at UCL Institute of Ophthalmology in 1999.